Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, Vasilakou D, Kakaletsis N, Tsapas A, Bekiari E

Diabetologia13 Apr 2024Cited by 79 (Europe PMC)

PMID38613667PMCIDPMC11153294DOI10.1007/s00125-024-06144-1PepBankPUB-38613667

Download PDF PubMedAsk about this study

Jump to 18 results

Summary

Aims/hypothesisWe conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus.MethodsWe searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA_1c and body weight from baseline. Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework.ResultsA total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA_1c (mean difference -21.61 mmol/mol [-1.96%]) followed by tirzepatide 10 mg (-20.19 mmol/mol [-1.84%]), semaglutide 2.0 mg (-17.74 mmol/mol [-1.59%]), tirzepatide 5 mg (-17.60 mmol/mol [-1.60%]), semaglutide 1.0 mg (-15.25 mmol/mol [-1.39%]) and semaglutide 0.5 mg (-12.00 mmol/mol [-1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia.Conclusions/interpretationOur data show that s.c. tirzepatide had a more pronounced effect on HbA_1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.RegistrationPROSPERO registration no. CRD42022382594.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg reduced HbA1c versus placebo and was the most efficacious treatment.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than placebo and was the most effective option.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change versus placebo, 15 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
Mean difference
−21.61 mmol/mol
15 mg vs placebo
Mean difference
−1.96%
15 mg vs placebo
Source sentences
Summary
Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA_1c (mean difference -21.61 mmol/mol [-1.96%])
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366701
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg reduced HbA1c versus placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change versus placebo, 10 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
Mean difference
−20.19 mmol/mol
10 mg vs placebo
Mean difference
−1.84%
10 mg vs placebo
Source sentences
Summary
tirzepatide 10 mg (-20.19 mmol/mol [-1.84%])
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366702
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg reduced HbA1c versus placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change versus placebo, 5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
Mean difference
−17.6 mmol/mol
5 mg vs placebo
Mean difference
−1.6%
5 mg vs placebo
Source sentences
Summary
tirzepatide 5 mg (-17.60 mmol/mol [-1.60%])
3 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366703
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, all tirzepatide doses lowered HbA1c comparably to semaglutide 2.0 mg and more than semaglutide 1.0 mg and 0.5 mg.
In plain wordsIn adults with type 2 diabetes, tirzepatide lowered HbA1c about as much as the highest semaglutide dose and more than lower semaglutide doses.
Peptide
Tirzepatide
Outcome
MixedHbA1c versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 and 15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366704
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide reduced body weight versus placebo, by 5.27 kg at 5 mg up to 9.57 kg at 15 mg.
In plain wordsIn adults with type 2 diabetes, tirzepatide led to more weight loss than placebo, rising with dose from 5.27 kg to 9.57 kg.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change versus placebo
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
5 to 15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
Weight reduction
5.27 to 9.57 kg
tirzepatide 5 to 15 mg vs placebo
Source sentences
Summary
Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366705
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15, 10 and 5 mg reduced body weight more than semaglutide 2.0, 1.0 and 0.5 mg, respectively.
In plain wordsIn adults with type 2 diabetes, each tirzepatide dose led to more weight loss than the matching semaglutide dose.
Peptide
Tirzepatide
Outcome
DecreaseBody weight versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 and 15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366706
07HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide increased the incidence of gastrointestinal adverse events versus placebo.
In plain wordsIn adults with type 2 diabetes, stomach and gut side effects were more common with tirzepatide than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events versus placebo
Study
n = 23,622
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
Both drugs increased incidence of gastrointestinal adverse events compared with placebo
3 context sentences(design, population, supporting numbers)
Summary · context
Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366707
08HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide did not increase the risk of severe hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, tirzepatide did not raise the risk of severe low blood sugar compared with placebo.
Peptide
Tirzepatide
Outcome
No significant changeSevere hypoglycaemia
Study
n = 23,622
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
5, 10 and 15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366709
09HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide did not increase the risk of serious adverse events.
In plain wordsIn adults with type 2 diabetes, tirzepatide did not raise the risk of serious side effects compared with placebo.
Peptide
Tirzepatide
Outcome
No significant changeSerious adverse events
Study
n = 23,622
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
5, 10 and 15 mg · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
while neither tirzepatide nor semaglutide increased the risk of serious adverse events
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcomes were achievement of HbA_1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia.
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366708
10HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide 2.0 mg lowered HbA1c versus placebo (mean difference -17.74 mmol/mol, -1.59%) in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, semaglutide 2.0 mg lowered HbA1c more than placebo in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus placebo, semaglutide 2.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
HbA1c mean difference
−17.74 mmol/mol
semaglutide 2.0 mg vs placebo
HbA1c mean difference
−1.59%
semaglutide 2.0 mg vs placebo
Source sentences
Summary
semaglutide 2.0 mg (-17.74 mmol/mol [-1.59%])
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366710
11HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide 1.0 mg lowered HbA1c versus placebo (mean difference -15.25 mmol/mol, -1.39%) in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered HbA1c more than placebo in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus placebo, semaglutide 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
HbA1c mean difference
−15.25 mmol/mol
semaglutide 1.0 mg vs placebo
HbA1c mean difference
−1.39%
semaglutide 1.0 mg vs placebo
Source sentences
Summary
semaglutide 1.0 mg (-15.25 mmol/mol [-1.39%])
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366711
12HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide 0.5 mg lowered HbA1c versus placebo (mean difference -12.00 mmol/mol, -1.09%) in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, semaglutide 0.5 mg lowered HbA1c more than placebo in a pooled analysis of trials.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus placebo, semaglutide 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
HbA1c mean difference
−12 mmol/mol
semaglutide 0.5 mg vs placebo
HbA1c mean difference
−1.09%
semaglutide 0.5 mg vs placebo
Source sentences
Summary
semaglutide 0.5 mg (-12.00 mmol/mol [-1.09%])
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366712
13HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide 2.0 mg lowered HbA1c about as much as all tirzepatide doses, while semaglutide 1.0 mg and 0.5 mg lowered it less.
In plain wordsIn adults with type 2 diabetes, semaglutide 2.0 mg lowered HbA1c about as much as tirzepatide; the 1.0 and 0.5 mg doses lowered it less.
Peptide
Semaglutide
Outcome
MixedHbA1c reduction versus tirzepatide, between-drug comparison
Study
n: not reported in source
Comparator
Tirzepatide 5, 10 and 15 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5, 1.0 and 2.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366713
14HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced body weight versus placebo by 2.52 kg (0.5 mg) to 4.97 kg (2.0 mg) in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered body weight more than placebo, by 2.52 to 4.97 kg depending on dose.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction versus placebo, semaglutide 0.5 to 2.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 to 2.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Measurements
body weight reduction vs placebo
2.52 to 4.97 kg
semaglutide 0.5-2.0 mg
Source sentences
Summary
Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg).
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with placebo
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366714
15HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide 2.0, 1.0 and 0.5 mg reduced body weight less than tirzepatide 15, 10 and 5 mg, respectively.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered body weight less than tirzepatide at matched dose steps.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction versus tirzepatide, between-drug comparison
Study
n: not reported in source
Comparator
Tirzepatide 15, 10 and 5 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
2.0, 1.0 and 0.5 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366715
16HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide increased the incidence of gastrointestinal adverse events compared with placebo.
In plain wordsIn adults with type 2 diabetes, semaglutide caused more stomach and gut side effects than placebo.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.5, 1.0 or 2.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
Both drugs increased incidence of gastrointestinal adverse events compared with placebo
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366716
17HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide did not increase the risk of serious adverse events compared with placebo.
In plain wordsIn adults with type 2 diabetes, semaglutide did not raise the risk of serious side effects compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.5, 1.0 or 2.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366717
18HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide did not increase the risk of severe hypoglycaemia compared with placebo.
In plain wordsIn adults with type 2 diabetes, semaglutide did not raise the risk of severe low blood sugar compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeSevere hypoglycaemia versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.5, 1.0 or 2.0 mg once weekly · subcutaneous · at least 12 weeksAs given in this study (human).
Source sentences
Summary
Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 28 trials with 23,622 participants (44.2% female) were included.
Show in the study text Report a problemFND-3861366718

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Summary

Results from this study18

Version history

Subjects

Publication types

MeSH terms

Keywords